Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Length of treatment and dose as determinants of mutagenicity in sickle cell disease patients treated with hydroxyurea.

Maluf S, Prá D, Friedrisch JR, Bittar C, da Silva MA, Henriques JA, Silla L.

Environ Toxicol Pharmacol. 2009 Jan;27(1):26-9. doi: 10.1016/j.etap.2008.08.004. Epub 2008 Aug 19.

PMID:
21791393
2.

DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.

Friedrisch JR, Prá D, Maluf SW, Bittar CM, Mergener M, Pollo T, Kayser M, da Silva MA, Henriques JA, da Rocha Silla LM.

Mutat Res. 2008 Jan 8;649(1-2):213-20. Epub 2007 Sep 29.

PMID:
17988936
3.
4.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

5.

Genotoxicity biomarkers in occupational exposure to formaldehyde--the case of histopathology laboratories.

Ladeira C, Viegas S, Carolino E, Prista J, Gomes MC, Brito M.

Mutat Res. 2011 Mar 18;721(1):15-20. doi: 10.1016/j.mrgentox.2010.11.015. Epub 2011 Jan 20.

PMID:
21256246
6.

Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.

Conran N, Fattori A, Saad ST, Costa FF.

Am J Hematol. 2004 Aug;76(4):343-7.

7.

Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk.

El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR.

Cancer Res. 2006 Jun 15;66(12):6449-56.

8.

Biomarkers measured by cytokinesis-block micronucleus cytome assay for evaluating genetic damages induced by polycyclic aromatic hydrocarbons.

Duan H, Leng S, Pan Z, Dai Y, Niu Y, Huang C, Bin P, Wang Y, Liu Q, Chen W, Zheng Y.

Mutat Res. 2009 Jun-Jul;677(1-2):93-9. doi: 10.1016/j.mrgentox.2009.06.002. Epub 2009 Jun 18.

PMID:
19540355
9.

A survey on the cytogenetic status of the Croatian general population by use of the cytokinesis-block micronucleus assay.

Garaj-Vrhovac V, Durinec M, Kopjar N, Orescanin V.

Mutat Res. 2008 Jan 8;649(1-2):91-100. Epub 2007 Sep 12.

PMID:
18029222
10.

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Acta Haematol. 1995;94(3):128-34.

PMID:
7502628
11.

Minimal doses of hydroxyurea for sickle cell disease.

Lima CS, Arruda VR, Costa FF, Saad ST.

Braz J Med Biol Res. 1997 Aug;30(8):933-40.

PMID:
9361721
13.

Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.

Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP.

Pediatr Blood Cancer. 2006 Dec;47(7):894-900.

PMID:
16526051
14.

Acquired DNA mutations associated with in vivo hydroxyurea exposure.

Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE.

Blood. 2000 Jun 1;95(11):3589-93.

15.
16.

Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome.

Brachet C, Azzi N, Demulder A, Devalck C, Gourdin A, Gulbis B, Klein A, Le PQ, Loop M, Sariban E, Ferster A.

Bone Marrow Transplant. 2004 Apr;33(8):799-803.

PMID:
14767501
17.

Cytokinesis-block micronucleus cytome assays for the determination of genotoxicity and cytotoxicity of cecal water in rats and fecal water in humans.

Benassi B, Leleu R, Bird T, Clifton P, Fenech M.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2676-80.

18.

The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.

el-Hazmi MA, al-Momen A, Warsy AS, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F.

Acta Haematol. 1995;93(2-4):57-61.

PMID:
7543719
19.

Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.

Iyamu EW, Cecil R, Parkin L, Woods G, Ohene-Frempong K, Asakura T.

Br J Haematol. 2005 Nov;131(3):389-94.

PMID:
16225659
20.
Items per page

Supplemental Content

Write to the Help Desk